Renaissance Technologies (RenTech)'s XLO Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 64,153 shares of Xilio Therapeutics, Inc. (XLO) worth $614,586, representing 0.00% of the portfolio. First purchased in 2022-Q2, this medium-term investment has been held for 17 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in XLO, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2026, adding 24,965 shares. Largest reduction occurred in Q1 2025, reducing 8,494 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Xilio Therapeutics (XLO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Xilio Therapeutics (XLO) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +14,587 | Add 29.43% | 64,153 | $9.58 |
| Q1 2026 | +24,965 | Add 101.48% | 49,566 | $8.41 |
| Q4 2025 | +9,980 | Add 68.26% | 24,601 | $8.96 |
| Q3 2025 | +2,892 | Add 24.66% | 14,621 | $11.80 |
| Q2 2025 | -964 | Reduce 7.59% | 11,729 | $9.52 |
| Q1 2025 | -8,494 | Reduce 40.09% | 12,693 | $10.14 |
| Q4 2024 | +2,166 | Add 11.39% | 21,187 | $13.37 |
| Q3 2024 | -2,050 | Reduce 9.73% | 19,021 | $11.03 |
| Q2 2024 | +3,253 | Add 18.26% | 21,071 | $13.27 |
| Q1 2024 | +2,839 | Add 18.95% | 17,818 | $15.10 |
| Q4 2023 | +13,500 | Add 912.78% | 14,979 | $7.68 |
| Q3 2023 | +29 | Add 2.00% | 1,479 | $29.75 |
| Q2 2023 | +107 | Add 7.97% | 1,450 | $0.04 |
| Q1 2023 | -1,307 | Reduce 49.32% | 1,343 | $0.04 |
| Q4 2022 | +614 | Add 30.16% | 2,650 | $0.04 |
| Q3 2022 | -3,343 | Reduce 62.15% | 2,036 | $40.77 |
| Q2 2022 | +5,379 | New Buy | 5,379 | $40.90 |
Renaissance Technologies (RenTech)'s Xilio Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Xilio Therapeutics, Inc. (XLO) in Q2 2022, acquiring 5,379 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Xilio Therapeutics, Inc. (XLO) for 17 quarters since Q2 2022.
Renaissance Technologies (RenTech)'s largest addition to Xilio Therapeutics, Inc. (XLO) was in Q1 2026, adding 49,566 shares worth $416,850.
According to the latest 13F filing for Q2 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 64,153 shares of Xilio Therapeutics, Inc. (XLO), valued at approximately $614,586.
As of the Q2 2026 filing, Xilio Therapeutics, Inc. (XLO) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Xilio Therapeutics, Inc. (XLO) was 64,153 shares, as reported at the end of Q2 2026.